Status:
RECRUITING
ProsTIC Registry of Men Treated With PSMA Theranostics
Lead Sponsor:
Peter MacCallum Cancer Centre, Australia
Conditions:
Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is a descriptive, observational, prospective, open-ended, registry utilising electronic data capture to collect information on the outcomes of men treated with prostate specific-membrane antigen ...
Detailed Description
The aim of the registry is to collect data of men with pre-treated metastatic castration-resistant prostate cancer (mCRPC) receiving Lutetium 177 (177Lu)-PSMA outside of a clinical trial to assess "re...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of mCRPC
- Progression or intolerance on a novel anti-androgen therapy (e.g. abiraterone, enzalutamide, apalutamide or darolutamide)
- Prior therapy with at least one taxane cytotoxic (these agents may have been received upfront for metastatic hormone-sensitive prostate cancer) or the patient is symptomatic and assessed as unfit for chemotherapy
- Referred to nuclear medicine and being considered for Lu-PSMA therapy according to institutional procedure guidelines
Exclusion
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04769817
Start Date
May 1 2021
End Date
December 31 2028
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia, 3000